Skip to main content

Table 2 Biomarker levels. Median [IQR] biomarker concentrations in patients according to positive or negative primary endpoint (KDIGO stage 2 or 3 AKI at 24 h)

From: Urinary cell cycle arrest biomarkers and chitinase 3-like protein 1 (CHI3L1) to detect acute kidney injury in the critically ill: a post hoc laboratory analysis on the FINNAKI cohort

 

AKI stage 2 or 3 at 24 h (n = 49)

AKI stage 0 or 1 at 24 h (n = 611)

p value

uCHI3L1 (ng/mL)

3.92 [0.12–12.45]

0.44 [0.12–2.42]

< 0.001

TIMP-2 (ng/mL)

6.40 [3.15–10.15]

3.40 [1.80–6.10]

< 0.001

IGFBP7 (ng/mL)

109.0 [46.9–300.9]

64.3 [32.4–128.9]

0.01

NephroCheck Risk® (ng/mL)2/1000

0.96 [0.19–2.64]

0.22 [0.06–0.85]

< 0.001

NephroCheck Risk® > 0.3 and ≤ 2.0 (ng/mL)2/1000

22/49 (44.9%)

190/611 (31.1%)

< 0.001

NephroCheck Risk® > 2.0 (ng/mL)2/1000

14/49 (28.6%)

75/611 (12.3%)

uCHI3L1•TIMP-2 (ng/mL)2

19.18 [1.34–113.50]

1.24 [0.27–13.95]

< 0.001

uCHI3L1•IGFB7 (ng/mL)2

199.6 [19.4–2932.9]

20.9 [5.1–221.7]

< 0.001

uCHI3L1•NephroCheck Risk® (ng/mL)3/1000

2.04 [0.11–28.13]

0.09 [0.01–1.31]

< 0.001

Back to article page

Critical Care

ISSN: 1364-8535